Table 4.
Resource Utilization by Product
| Axi-cel | Tisa-cel | P-value | |
|---|---|---|---|
| Treatment setting, n (%) | |||
| Inpatient | 144 (92%) | 31 (37%) | < 0.001 |
| Outpatient | 12 (8%) | 53 (63%) | --- |
| Unplanned hospitalization following outpatient administration, n (%)a | 1 (8%) | 19 (36%) | 0.062 |
| Reasons for hospitalization among outpatient administration, n (%)a | |||
| CRS | 0 (0%) | 8 (42%) | --- |
| ICANS | 1 (100%) | 2 (11%) | --- |
| Infection | 0 (0%) | 3 (16%) | --- |
| PD | 0 (0%) | 3 (16%) | --- |
| Other | 0 (0%) | 2 (11%) | --- |
| Missing | 0 (0%) | 1 (5%) | --- |
| Median LOS among those undergoing inpatient administration, days (IQR) | 19 (15-27) | 16 (10-19) | 0.001 |
| ICU transfer, n (%) | 60 (38%) | 4 (5%) | < 0.001 |
| ICU LOS, days (IQR) | 5 (3-8) | 2 (2-5) | 0.112 |
a
Within 28 days following CAR T cell infusion
Abbreviations: CRS = cytokine release syndrome; ICANS = immune effector cell-associated neurotoxicity syndrome; PD = progressive disease; LOS = length of stay; IQR = interquartile range; ICU = intensive care unit